US · Healthcare · Biotechnology
EPS came in at 0.61 against a street estimate of 0.17 — a beat of 258.8%.
Analysts rate PTC Therapeutics Inc a buy (13 buy, 2 hold, 1 sell out of 16) with an average price target of $100.47.
CONFIDENT PTC reported record product revenue, raised 2026 guidance, and reiterated strong long-term potential for Suffiance while advancing Fabry, Huntington’s, and Friedreich’s ataxia programs. Q3 FY26 The U.S. remains the majority of Suffiance revenue, while international growth is expected to accelerate as pricing and reimbursement are secured in additional markets. Analysts focused on Suffiance’s regional mix, durability, patient segments, and launch levers, alongside guidance, Fabry commercialization, and Votigern regulatory timing. Management emphasized sustained U.S. growth, international access expansion, disciplined BD, and continued clinical progress. 2026-10-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 16.73% |
| RTW INVESTMENTS, LLC | 9.28% |
| Jupiter Topco LLC | 8.67% |
| Vanguard Portfolio Management, LLC | 5.90% |
| State Street Corp | 5.51% |
| Wellington Management Company LLP | 4.95% |
| Vanguard Capital Management, LLC | 4.48% |
| Geode Capital Management, LLC | 2.64% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q4 2026 OTHER NOTABLE POINTS • On November 3, 2026, PTC Therapeutics, Inc. announced that its Board of Directors authorized a share repurchase program. • Th | 2026-11-03 |
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $357,807 thousand, up from $211,007 thousand in Q3 2025. • Nine-month 2026 revenue was $990,877 th | 2026-10-29 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 total revenue was $357.6 million, compared with $201.7 million in Q3 2025. • Product revenue was $275.9 million, up from | 2026-10-29 |
| Reg FD disclosure · Q3 2026 PTC THERAPEUTICS, INC. – FORM 8-K SUMMARY As of September 21, 2026 --- BUSINESS & SEGMENT HIGHLIGHTS • PTC Therapeutics completed acquisition of ST | 2026-09-21 |
| Material agreement · Q3 2026 PTC THERAPEUTICS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • PTC Therapeutics acquiring ST-920 asset from Sangamo Therapeutics for $111 million upfr | 2026-08-28 |
| Reg FD disclosure · Q3 2026 PTC THERAPEUTICS, INC. – FORM 8-K SUMMARY --- HEADLINE NUMBERS • Acquisition price: $111 million upfront plus up to $100 million in contingent mile | 2026-08-13 |
| Quarterly report · Q2 2026 PTC THERAPEUTICS, INC. – Q2 2026 SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Cash and marketable securities combined: $2,229.1 million (Jun | 2026-07-30 |
| Results announced · Q3 2026 PTC THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 total revenue: $361 million (product revenue $239 million) • Q2 2026 net incom | 2026-07-30 |
Readable in the app.
| Announcement | Date |
|---|---|
| Board authorized a $500 million share repurchase program PTC Therapeutics’ board authorized a share repurchase program allowing the company to buy back up to $500 million of its common stock. Purchases may occur at management’s discretion, dependi | 2026-11-03 |
| Full-year revenue and product revenue guidance raised PTC Therapeutics reported a strong third quarter, driven by its newer drug Sephience. Total revenue was $357.6 million, up from $201.7 million a year earlier, while commercial product revenu | 2026-10-29 |
| Completed acquisition; rolling BLA submission expected Q4 2026 PTC Therapeutics announced on September 21, 2026 that it completed an acquisition (specific target not detailed in this filing). The company is advancing a drug candidate called ST-920 towar | 2026-09-21 |
| Acquisition of ST-920 program for $111 million upfront plus contingent payments PTC Therapeutics announced it is acquiring a drug candidate called ST-920 for $111 million upfront, plus up to $100 million in additional payments if the drug receives FDA approval ($80 mill | 2026-08-13 |
| Financial guidance for fiscal year 2026 provided with forward-looking statements PTC Therapeutics filed an 8-K on January 12, 2026, primarily consisting of administrative disclosures rather than material business announcements. The filing indicates the company provided a | 2026-01-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for PTC Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.